Perrigo (NYSE:PRGO – Get Free Report) announced its earnings results on Wednesday. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81, Briefing.com reports. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.12 billion. Perrigo had a negative net margin of 2.81% and a positive return on equity of 6.79%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. Perrigo updated its FY 2024 guidance to 2.500-2.650 EPS and its FY24 guidance to $2.50 to $2.65 EPS.
Perrigo Price Performance
NYSE PRGO traded down $0.59 during mid-day trading on Friday, hitting $26.34. The stock had a trading volume of 239,083 shares, compared to its average volume of 1,618,630. Perrigo has a twelve month low of $23.89 and a twelve month high of $34.60. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.24. The stock has a market capitalization of $3.59 billion, a price-to-earnings ratio of -29.27 and a beta of 0.48. The firm’s 50 day moving average is $26.19 and its 200 day moving average is $27.52.
Perrigo Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 17th. Shareholders of record on Friday, November 29th will be given a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a yield of 4.19%. The ex-dividend date of this dividend is Friday, November 29th. Perrigo’s dividend payout ratio is presently -119.57%.
Insider Activity
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on PRGO. Jefferies Financial Group restated a “hold” rating and issued a $30.00 price objective (down previously from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. StockNews.com raised Perrigo from a “hold” rating to a “buy” rating in a report on Thursday. Piper Sandler cut their price target on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $42.00 price target on shares of Perrigo in a report on Monday, September 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.00.
Read Our Latest Stock Analysis on Perrigo
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
See Also
- Five stocks we like better than Perrigo
- What is a support level?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Where to Find Earnings Call Transcripts
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- L3Harris: Positioned for Gains With Trump’s Defense Policies
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.